Astro-Med, Inc. Reports Fourth Quarter and Fiscal 2011 Results; Directors Declare Quarterly Cash Dividend

March 15, 2011


Astro-Med, Inc. (NASDAQ: ALOT) reports Net Income on a GAAP basis of $517,000, equal to $0.07 per diluted share on sales of $17,857,000, for the Fourth Quarter ended January 31, 2011. During the comparable period of the previous year, the Company reported Net Income of $1,728,000 on a GAAP basis, equal to $0.23 per diluted share, on sales of $16,281,000.

Annual Net Sales and Income

Net Sales for the twelve month period of Fiscal Year 2011 were $71,016,000, a 10.9% increase over the prior year's Net Sales of $64,031,000. Net Income for Fiscal Year 2011 was $2,062,000, or $0.28 per diluted share, on a GAAP basis.

Growth in Sales and Gross Profit produced an improvement in the Company's Operating Income of $2,656,000, a 35% increase over the prior year's pre-litigation Operating Income.

Impact of Taxes, Foreign Currency, and Litigation

Annual Net Income of $2,062,000 includes a tax benefit of approximately $371,000, or $0.05 per diluted share, due to the favorable resolution of a previously uncertain tax position and a favorable adjustment in the filing of the prior year's tax returns. For the prior year, Fiscal 2010, the Company earned $2,766,000 in Net Income on a GAAP basis, representing $0.38 per diluted share.

Net Income in the Fourth Quarter of the prior year includes $335,000, equal to $0.04 per diluted share, from a tax benefit pertaining to a previously uncertain tax position. In addition, Net Income in the Fourth Quarter of the prior year included a gain of $112,000, equal to $0.02 per diluted share, related to the acquisition made on December 15, 2009, and $904,000, net of tax, related to the successful outcome of litigation, equal to $0.12 per diluted share. If non-recurring items were excluded from the Fourth Quarter of Fiscal 2010, Net Income for the prior year would have totaled $1,415,000, equal to $0.19 per diluted share.

Unfavorable foreign currency exchange rates of approximately $209,000 lowered Fourth Quarter sales by approximately 1.2%.

Commenting on the FY 2011 results, Albert W. Ondis, Chief Executive Officer, stated: "We are pleased to see that customer demand has returned to pre-recession levels and our backlog is back up. Customer demand was a healthy $72,600,000, representing a 13.2% increase over the prior year, and our year-end backlog increased by 25% to $7,114,000.

"I'm proud to say that the Company's Net Sales grew at a double digit rate of 11% during Fiscal 2011 with increases shared among each of our business segments; QuickLabel Systems, Test & Measurement, and Grass Technologies.

"It has been an exciting year for Astro-Med, Inc. with the introduction of new products in each of our business segments. QuickLabel Systems' new state of the art digital color label printer, the Vivo! Touch, was launched globally during the Fourth Quarter and is receiving an enthusiastic response from customers around the world. The Vivo! Touch, an intelligent color label printer, is expected to help Astro-Med set record sales in Fiscal 2012.

"Fiscal 2011 was the year that the Astro-Med Test & Measurement Product Group introduced its TMX high speed Data Acquisition System with its state of the art technology platform allowing high speed data capture, review, archiving, and analysis. Astro-Med Ruggedized Products continued to make gains with new orders for its cockpit printers and increased shipments to airplane companies.

"In the same year, the Grass Technologies Product Group introduced the TREA Ambulatory EEG Recorder, a 25 channel amplifier system which allows for 72 hours of acquisition and multiple sampling/storage rate options to its neurophysiology clinical customers.

"The Company's Balance Sheet remains solid at year end with $20,630,000 in Cash and Marketable securities, a Book Value of $7.50 per common share, and a 19% increase in cash dividend payments of $2,036,000 distributed to Astro-Med shareholders at $0.28 per share.

"Astro-Med, Inc. is well-positioned to continue its growth and profitability path into Fiscal 2012. We believe with the Company's new product offerings, we will reach record sales revenues and strong profits and achieve our mission of enhancing shareholder value."

Directors Declare Increase in Quarterly Dividend

On March 1, 2011, the Directors of Astro-Med, Inc. declared a regular quarterly cash dividend of $0.07 per share payable on April 1, 2011 to shareholders of record March 18, 2011.

Conference Call on Wednesday, March 16, 2011 at 11:00 am Eastern Daylight Savings Time

The Fourth Quarter conference call will be held on Wednesday, March 16, 2011 at 11:00 AM EDT. It will be broadcast in real time on the Internet through the Investing section of our website. We invite you to log on and listen in real time on March 16th, or to participate in the conference call by dialing 866-225-8754 with passcode 4403400. Following the live broadcast, an audio webcast of the call will be available for ten days at A conference call replay will also be available for ten days by dialing 800-406-7325 with passcode 4403400.

About Astro-Med, Inc.

Astro-Med, Inc. is a leading manufacturer of specialty high tech printing systems, electronic medical instrumentation, and test and measurement instruments. Astro-Med, Inc. products are sold under the brand names Astro-Med(R) Test & Measurement, Grass(R) Technologies, and QuickLabel(R) Systems and are employed around the world in a wide range of aerospace, medical, military, industrial, and packaging applications. Astro-Med, Inc. is a member of the Russell Microcap(R) Index. Additional information is available by visiting

                              ASTRO-MED, INC.
                  Consolidated Statements of Operations
                  In Thousands Except for Per Share Data
                           Three-Months Ended        Twelve-Months Ended
                        January 31,  January 31,  January 31,  January 31,
                           2011         2010         2011         2010
                        -----------  -----------  -----------  -----------
Net Sales               $    17,857  $    16,281  $    71,016  $    64,031
Gross Profit                  7,376        6,805       28,666  $    26,628
                               41.3%        41.8%        40.4%        41.6%
Operating Expenses:
   Selling                    4,341        3,895       16,690       15,342
   General &
    Administration              974        1,080        4,300        4,503
   Research &
    Development               1,282        1,254        5,020        4,820
                        -----------  -----------  -----------  -----------
                              6,597        6,229       26,010       24,665
Gain on Litigation               --        1,391           --        1,391
Operating Income                779        1,967        2,656        3,354
                                4.4%        12.1%         3.7%         5.2%
Other Income (Expense),
 Net                             (2)         134          128          328
                        -----------  -----------  -----------  -----------
Income Before Taxes             777        2,101        2,784        3,682
Income Tax Provision            260          373          722          916
                        -----------  -----------  -----------  -----------
Net Income              $       517  $     1,728  $     2,062  $     2,766
                        -----------  -----------  -----------  -----------
Net Income Per Share -
 Basic                  $      0.07  $      0.24  $      0.28  $      0.39
                        -----------  -----------  -----------  -----------
Net Income Per Share -
 Diluted                $      0.07  $      0.23  $      0.28  $      0.38
                        -----------  -----------  -----------  -----------
Weighted Average Number
 of Common Shares -
 Basic                        7,256        7,153        7,271        7,135
Weighted Average Number
 of Common Shares -
 Diluted                      7,417        7,446        7,470        7,375
Dividends Declared Per
 Common Share           $      0.07  $      0.06  $      0.28  $      0.24

Safe Harbor Statement

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include those mentioned in Astro-Med's FY2010 annual report and its quarterly filings with the Securities and Exchange Commission.

Albert W. Ondis
Joseph P. O'Connell
Astro-Med, Inc.
(401) 828-4000

SOURCE: Astro-Med, Inc.

IR Contact

AstroNova, Inc.
Investor Relations Department
600 East Greenwich Avenue
West Warwick, RI 02893
Scott Solomon
Senior Vice President Sharon Merrill
Phone: (617) 542-5300

Email Alerts

Email Address *

Enter the code shown above.

Interactive Analyst Center Disclaimer

The financial data and other material provided to users in the pages of the website is for information purposes only. Users should not rely on information on this website for any purpose other than for obtaining general knowledge of AstroNova. Material may be changed or updated without notice.

AstroNova, Inc.